90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
Indolent non-Hodgkin's lymphomas (NHLs) comprise 35-40% of all adult NHLs. No standard curative therapy exists for these malignancies. Newer therapies, including monoclonal antibodies and radioimmunotherapy, have had notable activity in chemotherapy-resistant patients. 90Yttrium-ibritumomab tiuxetan is a radioimmunoconjugate approved by the Food and Drug Administration in February 2002 for the treatment of relapsed and refractory, low-grade, follicular or transformed NHL. Reported response rates are 67-80%, with a median remission duration of approximately 12 months. Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. 90Yttrium-ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL.
The Ohio State University, Division of Hematology & Oncology, Arthur G. James Cancer Hospital, Columbus 43210-1240,, USA. blum-2@medctr.osu.edu
Kristie A
KA
Blum
Nancy L
NL
Bartlett
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D005544:Forecasting; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000532:radiotherapy*; D051379:Mice; D009503:Neutropenia / Q000209:etiology; D016499:Radioimmunotherapy; D011879:Radiotherapy Dosage; D013921:Thrombocytopenia / Q000209:etiology; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan